Amplia Therapeutics Price To Sales vs. Price To Earning
| INNMF Stock | USD 0.06 0 7.41% |
For Amplia Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Amplia Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Amplia Therapeutics Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Amplia Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Amplia Therapeutics Limited over time as well as its relative position and ranking within its peers.
Amplia |
Amplia Therapeutics Price To Earning vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Amplia Therapeutics's current stock value. Our valuation model uses many indicators to compare Amplia Therapeutics value to that of its competitors to determine the firm's financial worth. Amplia Therapeutics Limited is currently regarded as number one stock in price to sales category among its peers. It also is currently regarded as number one stock in price to earning category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amplia Therapeutics' earnings, one of the primary drivers of an investment's value.Amplia Price To Earning vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Amplia Therapeutics |
| = | 3.97 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Amplia Therapeutics |
| = | (1.12) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Amplia Price To Earning Comparison
Amplia Therapeutics is currently under evaluation in price to earning category among its peers.
Amplia Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Amplia Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Amplia Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Amplia Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Amplia Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase inhibitors for oncology and chronic fibrosis in Australia. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Innate Immunotherapeuti is traded on OTC Exchange in the United States.
Amplia Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Amplia Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Amplia Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Amplia Therapeutics' important profitability drivers and their relationship over time.
Use Amplia Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amplia Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amplia Therapeutics will appreciate offsetting losses from the drop in the long position's value.Amplia Therapeutics Pair Trading
Amplia Therapeutics Limited Pair Trading Analysis
The ability to find closely correlated positions to Amplia Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amplia Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amplia Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amplia Therapeutics Limited to buy it.
The correlation of Amplia Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amplia Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amplia Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amplia Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Amplia Therapeutics position
In addition to having Amplia Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Government Funds Thematic Idea Now
Government Funds
Funds or Etfs that invest in fixed income securities issued by national government to finance government spending or to facilitate Federal Reserve monetary policies. The Government Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Government Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Amplia Pink Sheet
To fully project Amplia Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Amplia Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Amplia Therapeutics' income statement, its balance sheet, and the statement of cash flows.